CClinicalTrials.gg
Status unknownNCT01238003Updated Nov 10, 2010

Clinical Relevance of Anti-Neutrophil Cytoplasm Antibody (ANCA)in Hospitalized Patients

An observational study in ANCA-related Vasculitis, sponsored by Hillel Yaffe Medical Center. Status unknown at 1 site in Israel. Per ClinicalTrials.gov, last updated 2010-11-10.

Sponsored by Hillel Yaffe Medical Center · Observational

The sponsor has not verified this record recently (last verified Nov 2010), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
380
Sex
All
01

Study summary

Laboratory testing of Anti-Neutrophil Cytoplasm Antibody (ANCA) is used to confirm diagnosis of patients who have a high level of suspicion for ANCA-related vasculitis. In these patients the specificity and sensitivity to the ANCA test is very high. This study hopes to prove that when this lab test is performed on blood of patients who do not have a high level of suspicion for ANCA-related vasculitis, the sensitivity and specificity is reduced and there are many false positive results. Because of this, it should not be used as a screening test for a more general patient population.

02

Conditions studied

  • ANCA-related Vasculitis

Browse trials for

03

In context

Vasculitis

230 studies on the registry are indexed under Vasculitis; 68 are open to participants now.

This study's planned enrollment of 380 is above the median of 149 across 104 observational studies indexed under Vasculitis.

Browse Vasculitis studies →

Lead sponsor

Hillel Yaffe Medical Center is the lead sponsor of 301 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients hospitalized in internal medicine ward

Inclusion criteria

  • Blood samples sent for ANCA lab test

Exclusion criteria

Exclusion Criteria:

  • Patients with ANCA vasculitis
  • Patients with known malignancy
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
380 participants (estimated)

Groups and cohorts

  • Hospitalized patients

    Other: Interpretation of blood test results

Interventions

  • OtherInterpretation of blood test results

    Interpretation of blood test results

06

What researchers measure

Primary outcomes

  1. Mostly negative lab results

    Time frame: One year

07

Study locations

1 site
  • Hillel Yaffe MC,
    Hadera, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01238003
Lead sponsor
Hillel Yaffe Medical Center
First posted
Nov 10, 2010
Start date
Dec 2010
Primary completion
Dec 2011 (estimated)
Completion
Dec 2011 (estimated)
Last update
Nov 10, 2010

Study contacts

Nina Avshovich, MD
Contact
ninaa@hy.health.gov.il
972-52-5566049
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion